National Bank of Canada
INBS icon

National Bank of Canada’s Intelligent Bio Solutions INBS Stock Holding History

National Bank of Canada’s Portfolio INBS Stock Details INBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35
Closed -$332 – 3081
2025
Q4 		$332 Hold
35
– – ﹤0.01% 2717
2025
Q3 		$354 Hold
35
– – ﹤0.01% 2715
2025
Q2 		$598 Buy
+35
New +$503 ﹤0.01% 2754

Other funds holding INBS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CW
Curio Wealth Annapolis, Maryland $293M AUM 14.23% 1-Year Est. Return

National Bank of Canada's INBS Position: Q1 2026 in Review

National Bank of Canada sold out of Intelligent Bio Solutions (INBS) in Q1 2026, closing a stake of 35 shares — an estimated $332 sold.

National Bank of Canada first reported a position in INBS in Q2 2025 and held it in 3 quarters. The position peaked at $598 in Q2 2025. 9 funds tracked by Wall St. Rank hold INBS as of Q1 2026.

  • National Bank of Canada reported no remaining Intelligent Bio Solutions position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 35 Intelligent Bio Solutions shares in Q1 2026, an estimated $332.
  • National Bank of Canada first reported a position in Intelligent Bio Solutions in Q2 2025 and held it in 3 quarters.
  • National Bank of Canada's Intelligent Bio Solutions position peaked at $598 in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Intelligent Bio Solutions as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.